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Abstract: Materials based on biodegradable polyesters such as poly(butylene terephthalate) (PBT) 20 
or poly(butylene terephthalate-co-poly(alkylene glycol) terephthalate) (PBTAT) have potential 21 
application as pro-regenerative scaffolds for bone tissue engineering. Herein is reported the 22 
preparation of films composed of PBT or PBTAT and an engineered spider silk protein, 23 
(eADF4(C16)), that displays multiple carboxylic acid moieties capable of binding calcium ions and 24 
facilitating their biomineralization with calcium carbonate or calcium phosphate. Human 25 
mesenchymal stem cells cultured on films mineralized with calcium phosphate show enhanced 26 
levels of alkaline phosphatase activity suggesting that such composites have potential use for bone 27 
tissue engineering. 28 
Keywords: spider silk; recombinant protein; biodegradable polymers; biomaterials; 29 
biomineralization; bone tissue engineering. 30 
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 32 
1. Introduction 33 
Bones are composed of mixtures of inorganic material, predominantly calcium phosphate in the 34 
form of carbonated hydroxyapatite and organic material, predominantly collagen, and many 35 
different materials and manufacturing methodologies are used in the development of bone tissue 36 
scaffolds [1]. While non-biodegradable materials (e.g. metals, polyethylene and 37 
polyetheretherketone [2,3]) are commonly used to manufacture components for certain applications 38 
in bone tissue, for instance hip replacements, there are issues with these materials such as 39 
inflammation, metal sensitivity and toxicity, and solutions to these issues are the subject of ongoing 40 
research [2,3]. Biodegradable materials are of particular interest because their eventual resorption 41 
allows them to be remodelled in vivo, and biodegradable polymer-based materials and composites 42 
based thereon are popular avenues of research [4-15]. 43 
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Poly(butylene terephthalate) (PBT) and its copolymers with poly(ethylene oxide) (e.g. PBTAT 44 
derivatives) are biodegradable polymers that are easy to process into films, fibers and foams [16-19]. 45 
Scaffolds based on PBT and/or PBTAT have been demonstrated to be suitable substrates for the 46 
attachment and proliferation of chondrocytes, mammalian skeletal muscle cells [19], bone marrow 47 
stromal cells [18], and human mesenchymal stem cells [17] in vitro. Preclinical studies in various 48 
animal models showed that the degradation rate of scaffolds based on PBT and/or PBTAT were 49 
dictated by the precise composition of the polymer backbone which suggests it may be possible to 50 
tailor-make such materials for specific conditions or patients; and in mammals PBTAT-based 51 
materials encouraged bone growth, which motivates the development of PBT-/PBTAT-based 52 
scaffolds for bone regeneration [20-23]. 53 
Silk protein-based materials are also candidates for the generation of tissue scaffolds [24-31]. 54 
The natural silk fibroin of the domesticated Bombyx mori silkworm is the most commonly 55 
investigated for such applications [24-32], however, recombinantly produced silk-inspired proteins 56 
represent interesting alternatives because it is possible to produce large quantities of such silks with 57 
designed primary sequences [33-37]. Silk-based composites are also widely investigated for 58 
application as tissue scaffolds [37-40], and preclinical trials in animal models are promising 59 
[35,36,41]. 60 
Scheibel and coworkers have developed engineered spider silks based on the two most 61 
abundant proteins found in the dragline silks of the European garden spider (Araneus diadematus, 62 
A. diadematus fibroin 3 and 4, ADF3 and ADF4 respectively); the engineered silk protein analogues 63 
(eADF3 and eADF4 respectively), can be produced by an industrially viable fermentation process in 64 
Escherichia coli bacteria [42-45]. The repetitive backbone sequence of eADF4 analogues displays 65 
numerous glutamic acid residues [42] enabling their chemical modification [46] or binding cations 66 
such as drugs [47]. 67 
This manuscript describes the preparation and characterization of composites of PBT or PBTAT 68 
with an eADF4 analogue, namely eADF4(C16), and their biocompatibility as assayed with 69 
fibroblasts (M-MSV-BALB/3T3) and human mesenchymal stem cells. Moreover, mineralization of 70 
these composites with calcium phosphate enhanced the levels of alkaline phosphatase activity of 71 
human mesenchymal stem cells cultured on the substrates, and therefore they are potentially useful 72 
for integration in biodegradable devices applied in bone tissues [48]. Such materials have prospects 73 
for application in tissue engineering and regenerative medicine, for use in various bone tissue 74 
specific niches. 75 
2. Materials and Methods  76 
2.1. Materials 77 
Unless otherwise stated, all chemicals were of ACS grade, purchased from Sigma-Aldrich 78 
Chemie GmbH and used as supplied. Reagents for cell culture were purchased from Invitrogen 79 
(Carlsbad, CA) unless otherwise noted. Human mesenchymal stem cells (HMSCs) were purchased 80 
from Lonza Cologne GmbH (Cologne, Germany). High glucose Dulbecco’s Modified Eagle Medium 81 
(DMEM) and fetal bovine serum (FBS) were purchased from Biochrom AG (Berlin, Germany). The 82 
recombinantly produced silk protein was based on the consensus motif of the repetitive core domain 83 
of one of the major ampullate silk fibroins of the garden cross spider (A. diadematus fibroin 4). The 84 
recombinant protein is composed of sixteen repeats of the polypeptide module C (amino acid 85 
sequence: GSSAAAAAAAASGPGGYGPENQGPSGPGGYGPGGP), and is referred to hereafter as 86 
eADF4(C16). Production and purification of eADF4(C16) was carried out as described previously 87 
[42]. 88 
2.2. Film preparation, thermogravimetric analysis (TGA), X-ray diffraction (XRD), Fourier transform infrared 89 
(FTIR) spectroscopy, in vitro degradation studies, and in vitro fibroblast adhesion studies 90 
Adapted from previously described methodology [47], for full experimental details refer to the 91 
Supporting Information. 92 
Materials 2016, 9, x 3 of 14 
 
2.3. Mineralization of films with calcium carbonate 93 
Three beakers (10 mL) containing crushed ammonium carbonate were also covered with 94 
Parafilm® punched with three needle holes and placed at the bottom of a large desiccator, above 95 
which films cast in 24 well tissue culture plates were incubated in an aqueous solution (1 mL) of 96 
calcium chloride (25 mM), and covered with Parafilm® punched with three needle holes. The 97 
dessicator was sealed and the samples left for 72 hours. The samples were subsequently washed 98 
with water until the pH was neutral, and then with ethanol/water (70 % ethanol, 30% water) and 99 
allowed to dry in a sterile fume hood overnight. 100 
2.4. Mineralization of films with calcium phosphate 101 
Films cast in 24 well tissue culture plates were incubated in an aqueous solution (1 mL) of 102 
calcium chloride (200 mM) for 20 minutes, after which the solution was removed and the samples 103 
were washed with water (3 x 1 mL). Thereafter, samples were incubated in an aqueous solution (1 104 
mL) of sodium phosphate (120 mM) for 20 minutes, after which the solution was removed and the 105 
samples were washed with water (3 x 1 mL). The cycle of incubation with calcium chloride and 106 
sodium phosphate was repeated a further six times (i.e. a total of 7 cycles), after which the samples 107 
were incubated in ethanol/water (70% ethanol, 30% water) for 30 minutes and allowed to dry in a 108 
sterile fume hood overnight. 109 
22.5. Scanning Electron Microscopy (SEM) and Energy Dispersive Spectroscopy (EDS) 110 
Samples were mounted on metal stubs, coated with Pt/Pd or Carbon using a Cressington 208 111 
benchtop sputter coater before being observed with a Hitachi S5500 SEM equipped with an EDS 112 
probe. 113 
2.6. Stem cell culture and qualitative and quantitative studies of alkaline phosphatase activity 114 
Commercially available Nunclon® Δ surface tissue culture plates were used for control 115 
experiments. Silk films were sterilized by incubation in 70% ethanol solution followed by exposure 116 
to UV for 60 minutes. After sterilization, the samples were incubated for 30 minutes under 3 mm of 117 
HMSC growth medium. HMSC growth medium was composed of: high glucose Dulbecco’s 118 
Modified Eagle Medium (DMEM, 440 mL); fetal bovine serum (50 mL); antibiotic-antimycotic (5 119 
mL); non-essential amino acids (5 mL), and 2 ng/mL basic fibroblast growth factor. Medium was 120 
aspirated and replaced prior to HMSC seeding. Cell viability before starting the experiment was 121 
determined by the Trypan Blue exclusion method, and the measured viability exceeded 95% in all 122 
cases. HMSCs were seeded at 10,000 cells/cm2 under 3 mm of medium, and incubated at 37°C, 95% 123 
humidity, and a CO2 content of 5%. After 3 days the medium was aspirated, the films were washed 124 
gently with PBS and replaced with osteogenic medium. Osteogenic medium was composed of: high 125 
glucose Dulbecco’s Modified Eagle Medium (DMEM, 425 mL); fetal bovine serum (50 mL); 126 
antibiotic-antimycotic (5 mL); non-essential amino acids (5 mL), dexamethasone (100 nM), β-glycerol 127 
phosphate (10 mM) and ascorbic acid (50 µM). Thereafter the osteogenic medium was aspirated and 128 
replaced every 2 days until the samples were analysed. Alkaline Phosphatase (ALP) activity was 129 
visualized with a Leukocyte Alkaline Phosphatase Kit using the manufacturer’s protocol. Images of 130 
stained cells were obtained using a camera AxioCam MRm attached to a Zeiss Axio Observer Z1 131 
equipped with an ApoTome unit. Images are representative of 3 samples. DNA was quantified 132 
using PicoGreen® assay (Life Technologies GmbH, Darmstadt, Germany) using a Synergy HT 133 
Multi-Mode Microplate Reader (Bio-tek Instruments GmbH, Bad Friedrichshall, Germany). ALP 134 
activity of the cell population was quantified by first scraping and breaking up the films in a buffer 135 
of 0.2% Triton X-100, and then measuring ALP activity using an ALP LiquiColor® kit (Stanbio, 136 
Boerne, TX) in accordance with the manufacturer’s protocol. The sample and reagents were 137 
incubated in a 96 well plate for 1 h at 37°C and then read using a Synergy HT Multi-Mode 138 
Microplate Reader (Bio-tek Instruments GmbH, Bad Friedrichshall, Germany). Data were 139 
normalized to DNA quantity. Statistical analysis via ANOVA (null hypothesis that all groups have 140 
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the same true mean, P-value < 0.0001) carried out within R (http://www.r-project.org/), and one way 141 
ANOVA statistics were calculated and interpreted with Tukey’s T-test, for which any interval that 142 
does not cross zero (the dashed line) is significant with an alpha = 0.05 [9]. 143 
3. Results and Discussion 144 
3.1. Film preparation and characterization 145 
The compositions of the films described herein are found in Table 1. All films had thicknesses of 146 
ca. 100 µm, and therefore would not be expected to be encapsulated inside a very thick foreign body 147 
capsule in vivo [47]. Thermogravimetric analysis revealed that “as cast” films contained residual 148 
volatiles (HFIP and water), levels of which were diminished by immersion of the films in methanol 149 
(Figures S1–S9, Supporting Information). 150 
Analysis of the films by X-ray diffraction (Figures S1–S9 and Table S1, Supporting Information) 151 
was informative, confirming that the eADF4(C16) silk component of the “as cast” films was water 152 
soluble due to its α-helix rich nature (XRD peaks at 2θ = 14.4° and 19.4°) induced by the HFIP used in 153 
the casting process [47], and that methanol treatment rendered the silk component of films insoluble 154 
in water due to induction of β-sheet formation (XRD peaks at 2θ = 16.7°, 19.9°, 24.0°, and 31.8°, in 155 
agreement with literature data), suggesting that this process removes residual HFIP [47]. The peak 156 
positions for PBT [49,50] or PBTAT [49,50] are in line with those reported in the literature for each 157 
polymer, respectively. Interestingly, the XRD spectra of the films composed solely of PBT or PBTAT 158 
revealed that they became more crystalline after treatment with methanol, which supports our 159 
assertion that methanol treatment removes residual HFIP that solvates the polymers, thereby 160 
deterring their crystallization. XRD spectra of films composed of mixtures of eADF4(C16) and the 161 
PBT or PBTAT displayed peaks due to the combinations of the two components, however, the 162 
signals of eADF4(C16) were normally only evident as shoulders on the peaks due to the more 163 
crystalline PBT or PBTAT. 164 
FTIR spectroscopy confirmed that HFIP (Figure S10, Supporting Information) was present in 165 
the “as cast” films (strong absorption at 1105 cm-1), and that it could effectively be removed by 166 
methanol treatment, as the absorption was markedly diminished or absent (Figures S1–S9, 167 
Supporting Information). Furthermore, FTIR spectroscopy confirmed the silk component of the as 168 
cast films to be α-helix rich (amide I and II peaks were observed at 1656 and 1547 cm-1, respectively), 169 
whereas the methanol treated films were β-sheet rich (amide I and II absorptions were shifted to 170 
1625 and 1521 cm-1 respectively, and a peak at 965 cm-1 assigned to polyalanine-based β-sheets).  171 
Visual observation of the “as cast” and “methanol treated” films by photography and bright 172 
field microscopy (Figures S1–S9, Supporting Information), revealed a degree of phase separation 173 
between the eADF4(C16) and PBT or PBTAT (analogous to that observed for composites of 174 
eADF4(C16) and polycaprolactone or Pellethane 2363-80A) [47]. Differences in the optical properties 175 
of the components of the films (the silk being relatively clear, and the PBT/PBTAT being relatively 176 
opaque) enabled the assignment of the component constituting the continuous phase as reported in 177 
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eADF4(C16) 100:0 eADF4(C16) 72.0 ± 8.0 S1 and Ref. 47 
PBT-25 75:25 eADF4(C16) 55.5 ± 5.9 S2 
PBT-50 50:50 PBT 58.9 ± 8.0 S3 
PBT-75 25:75 PBT 69.8 ± 10.0 S4 
PBT-100 0:100 PBT 75.8 ± 3.5 S5 
PBTAT-25 75:25 eADF4(C16) 76.9 ± 6.6 S6 
PBTAT-50 50:50 PBTAT 104.5 ± 4.4 S7 
PBTAT-75 25:75 PBTAT 76.4 ± 2.4 S8 
PBTAT-100 0:100 PBTAT 69.3 ± 2.4 S9 
Untreated 
Nunclon® 
Not applicable Not applicable 74.0 ± 6.2 S11 
Nunclon® Δ 
Surface 
Not applicable Not applicable 100.0 ± 7.5 Ref. 47 
 191 
3.2. In vitro degradation studies 192 
A biomaterial's performance in vivo is influenced by its stability and degradation profile. For 193 
tissue engineering applications materials that degrade are attractive as they can be replaced by 194 
native extracellular matrix, and it is useful to be able to tune the degradation behavior of 195 
biomaterials [24,32,51]. Trypsin and elastase were chosen as biologically relevant model proteolytic 196 
enzymes that play roles in digestion and wound healing, respectively. The in vitro degradation of 197 
the films in solutions of elastase and trypsin in phosphate buffered saline (PBS) was studied over the 198 
period of 250 hours (Figures S1–S9, Supporting Information). Spontaneous hydrolysis of 199 
eADF4(C16), PBT and PBTAT has been reported to be negligible (<2%) as they are insoluble in water, 200 
and hydrolysis of the amides and esters in their respective backbones is a very slow process 201 
[22-24,47]. In the presence of elastase and trypsin the films composed solely of eADF4(C16) were 202 
observed to degrade slowly and had sufficient structural integrity to be manipulated for over 250 203 
hours (Figure S1, Supporting Information). Mass loss profiles recorded using the same procedure for 204 
PBT-25 (Figure S2, Supporting Information) and PBTAT-25 (Figure S6, Supporting Information) 205 
films showed that they degraded more swiftly, in part because their phase separated nature formed 206 
the basis for small parts of the film separating from the bulk; their degradation profiles are included 207 
for completeness and not representative solely of the enzymatic degradation of the silk protein. The 208 
structural integrity of all of the other films was maintained for the duration of the experiments, and 209 
the data are therefore representative of the enzymatic degradation of the silk protein, and mass loss 210 
was faster from films with higher eADF4(C16) content. Clearly, it would be expected that the 211 
degradation of the films in vivo would be markedly slower than that of our in vitro assay, in line 212 
with the literature precedent for Nephila clavipes spider silk [52], B. mori silkworm silk [41], or the 213 
polyesters [22,23], respectively. 214 
3.3. In vitro fibroblast adhesion studies 215 
BALB/3T3 mouse fibroblast adhesion to the films was assayed using Alamar Blue, with two 216 
commercially available surfaces as references for our studies, untreated polystyrene tissue culture 217 
plates (Nunclon®) and plasma treated polystyrene tissue culture plates (Nunclon® Δ Surface), and 218 
cell adhesion is reported relative to the Nunclon® Δ surface [46,47]. Since the cells were in a 219 
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quasi-steady-state situation, increasing values of fluorescence are proportional to the number of 220 
cells, observing fibroblast adhesion on all of the films (Table 1 and Supporting Information). 221 
Fibroblast adhesion to films incorporating PBT or PBTAT was in all cases better than to films 222 
composed of eADF4(C16) alone (which already have been described to be a poor surface for 223 
fibroblast adhesion),  and generally comparable to levels of adhesion observed for the untreated 224 
Nunclon® tissue culture plates; interestingly, levels of cell adhesion to PBTAT-50 films were similar 225 
to that on plasma treated Nunclon® Δ Surface tissue culture plates. Cells were clearly observable on 226 
the optically clear films of eADF4(C16) and tissue culture plates (Figure S1, S11 and [47], 227 
respectively), whereas cells on the composite films were more easily visualized after Calcein A/M 228 
staining (Figures S2-S9, Supporting Information). 229 
3.4. Film biomineralization with calcium carbonate or calcium phosphate 230 
With a view to the application of the materials as scaffolds for bone tissue engineering, the films 231 
were biomineralized [53,54] with calcium carbonate or calcium phosphate. Mineralization of the 232 
films with calcium carbonate was achieved by incubation of the films in solutions of calcium 233 
chloride in a container with ammonium carbonate, and mineralization of the films with calcium 234 
phosphate was achieved by iterative sequences of incubation of the films in solutions of calcium 235 
chloride followed by sodium phosphate. The engineered silk eADF4(C16) displays multiple 236 
carboxylic acid moieties capable of binding calcium ions facilitating their mineralization. Energy 237 
dispersive spectroscopy (EDS) analysis of the films confirmed that the surface chemistry of the films 238 
before and after mineralization was different. Peaks in the EDS spectra of the eADF4(C16) and 239 
composite films prior to mineralization have lines at 0.277, 0.525, and 1.041 keV that are the 240 
characteristic Kα emissions of carbon, oxygen and sodium, respectively, and the weak emission at 241 
0.392 keV is the Kα emission of nitrogen (Figure 1). After the mineralization, new peaks appeared in 242 
the spectra at 2.013, 2.621 and 3.690 keV which are the characteristic Kα emission line of 243 
phosphorous, chlorine (from the calcium chloride used as a source of Ca2+) and calcium, respectively 244 
(Figure 1). Imaging with SEM-EDS revealed that calcium carbonate was preferentially deposited in 245 
the eADF4(C16) phase of the films, as opposed to the PBT or PBTAT phases, whereas the calcium 246 
phosphate was deposited more homogeneously across the surface of the films (as depicted in 247 
schematic format in Figure 1); this is likely to be caused by differences in the concentration of 248 
calcium chloride solution in which the films were incubated, 25 mM for calcium carbonate 249 
mineralization as opposed to 200 mM for calcium phosphate deposition (examples for PBT-50 and 250 
PBTAT-50 are displayed in Figure 2). 251 
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 252 
Figure 1. Schematic of biomineralization of films with representative EDS analysis of films. 253 
3.5. In vitro stem cell culture 254 
Human mesenchymal stem cells were cultured in vitro for 2 weeks on calcium phosphate 255 
mineralized films. Alkaline phosphatase (ALP) activity is a hallmark of bone tissue formation, and 256 
therefore both qualitative and quantitative analyses of ALP activity were studied. Qualitative 257 
analysis of ALP activity using ALP live staining (Figure 3, A-J) showed that the cells were alive and 258 
functional on the films as seen by the patches of dark coloration that is characteristic of the 259 
precipitated stain. Quantitative analysis of ALP activity for the cells cultured on the mineralized 260 
films (Figure 4) showed that ALP activity (Figure 4A) was correlated with levels of fibroblast 261 
adhesion (Table 1). The one-way analysis of variance (ANOVA) was used to determine whether 262 
there were any significant differences in the quantitative analyses of ALP activity (Figure 4B), and 263 
the one-way ANOVA rejects the null hypothesis that all groups have the same true mean (P-value < 264 
0.0001). Consequently, Tukey's T-test was used to compare differences between groups, where any 265 
interval that does not cross zero (the dashed line in Figure 4B) is significant with an alpha = 0.05. 266 
Interestingly, levels of ALP activity for the cells cultured on Nunclon® Δ were significantly different 267 
from all other films. Levels of ALP activity for the cells cultured on mineralized eADF4(C16) were 268 
not significantly different from the mineralized PBT composites, or indeed the pure PBT or PBTAT; 269 
however, statistically significant differences were observed for mineralized PBTAT-50 and 270 
PBTAT-75, wherein ALP activity for cells cultured on these materials was higher than for either of 271 
the constituents (eADF4(C16) or PBTAT) alone (and logically the PBT composites). Together, this 272 
suggests that composites of eADF4(C16) and PBTAT have some potential for bone tissue 273 
engineering. 274 
 275 
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 276 
Figure 2. SEM-EDS analysis of films. A-D) PBT-50. E-H) PBT-50-CaCO3. I-L) PBT-50-CaPO4. M-P) 277 
PBTAT-50. Q-T) PBTAT-50-CaCO3. U-X) PBTAT-50-CaPO4. A, E, I, M, Q, U) Secondary electron SEM 278 
image. B, F, J, N, R, V) Carbon, red. C, G, K, O, S, W) Calcium, yellow. D, H, L, P, T, X) Phosphorous, 279 
blue. Scale bar represents 40 µm. 280 
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 281 
Figure 3. A-J) Qualitative analysis of ALP activity of stem cells on films mineralized with calcium 282 
phosphate using bright field microscopy after ALP live staining. A) Nunclon® Δ. B) 283 
eADF4(C16)-CaPO4. C) PBT-25-CaPO4. D) PBT-50-CaPO4. E) PBT-75-CaPO4. F) PBT-100-CaPO4. G) 284 
PBTAT-25-CaPO4. H) PBTAT-50-CaPO4. I) PBTAT-75-CaPO4. J) PBTAT-100-CaPO4. Images are 900 285 
µm wide. 286 
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 287 
Figure 4. A) Quantitative analysis of ALP activity of stem cells on films mineralized with calcium 288 
phosphate. B) Statistical analysis via ANOVA (null hypothesis that all groups have the same true 289 
mean, P-value < 0.0001), and one way ANOVA statistics were calculated and interpreted with 290 
Tukey’s T-test, for which any interval that does not cross zero (the dashed line) is significant with an 291 
alpha = 0.05. 292 
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4. Conclusions  293 
Films composed of natural and recombinantly produced silk proteins have been widely 294 
investigated for biomedical applications such as biocompatible coatings for biomedical implants, 295 
owing to the facility with which silk proteins can be processed into films with tunable surface 296 
properties (morphology, hydrophilicity, etc.), their biodegradability and low levels of 297 
immunogenicity in vitro/in vivo. This manuscript reports a simple method of producing films 298 
composed of a recombinantly produced spider silk inspired protein eADF4(C16) and biodegradable 299 
polymers (PBT and PBTAT), their mineralization with either calcium carbonate or calcium 300 
phosphate, and a preliminary in vitro cell culture experiment to assess their efficacy for bone tissue 301 
engineering. Interestingly, levels of ALP activity for HMSCs residing on calcium phosphate 302 
mineralized PBTAT-50 and PBTAT-75 films were elevated when compared to the other formulations 303 
investigated or indeed the constituents alone, and it is concluded that such composites have 304 
potential for the development of functional biomineralized biomaterials [55-62]. 305 
Supplementary Materials: The following are available online at www.mdpi.com/link, Figure S1: eADF-4(C16) 306 
films. Figure S2: PBT-25 films. Figure S3: PBT-50 films. Figure S4: PBT-75 films. Figure S5: PBT-100 films. Figure 307 
S6: PBTAT-25 films. Figure S7: PBTAT-50 films. Figure S8: PBTAT-75 films. Figure S9: PBTAT-100 films. Table 308 
S1: Positions of XRD peaks of films determined using Jade 9 XRD Pattern Processing software. Figure S10: FTIR 309 
spectrum of pure HFIP. Figure S11: Bright field microscope image of fibroblasts cultured on Nunclon® Tissue 310 
Culture Plate (scale bar represents 100 µm). 311 
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